Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $7.95, for a total value of $91,003.65. Following the transaction, the director now directly owns 7,218,414 shares in the company, valued at approximately $57,386,391.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total value of $87,684.02.
- On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total value of $100,962.54.
- On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.79, for a total value of $216,382.66.
- On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total value of $241,851.24.
- On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $247,065.28.
- On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total value of $106,457.10.
Recursion Pharmaceuticals Trading Up 5.4 %
A letter is coming from the "Bureau of the Fiscal Service".
From Stansberry Research | Ad
Is your bank next?
A powerful new trend is spreading like wildfire inside the US financial system. At least 41 banks are already involved. But the Federal Reserve predicts that number will grow fast.
See if your bank is involved right here.
RXRX opened at $8.79 on Friday. Recursion Pharmaceuticals, Inc. has a one year low of $4.55 and a one year high of $16.75. The business's fifty day moving average is $10.10 and its two-hundred day moving average is $9.16.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million during the quarter, compared to analysts' expectations of $12.37 million. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently weighed in on the company. TD Cowen assumed coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a "market perform" rating on the stock. Needham & Company LLC restated a "buy" rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Finally, KeyCorp lifted their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Monday, March 4th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $12.75.
Read Our Latest Stock Report on Recursion Pharmaceuticals
Hedge Funds Weigh In On Recursion Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Recursion Pharmaceuticals in the first quarter worth $26,000. National Bank of Canada FI increased its stake in Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company's stock valued at $31,000 after purchasing an additional 1,500 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Recursion Pharmaceuticals by 116.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company's stock valued at $40,000 after purchasing an additional 2,817 shares during the last quarter. First Horizon Advisors Inc. acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at $47,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Recursion Pharmaceuticals by 25.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company's stock valued at $77,000 after purchasing an additional 2,050 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
